Biosynthesized Silver Nanoparticles Inhibit Osteoclastogenesis by Suppressing NF-κB Signaling Pathways.

Area of Science:

• Biomaterials Science
• Nanotechnology
• Immunology

Background:

• Overactive osteoclasts drive inflammatory bone loss.
• Reactive oxygen species (ROS) exacerbate osteoclast formation and function.
• Silver nanoparticles (Ag NPs) show potential for mitigating bone loss due to ROS scavenging properties.

Purpose of the Study:

• To synthesize and characterize low-toxicity, stable Ag NPs using Flos Sophorae Immaturus extract.
• To evaluate the efficacy of these Ag NPs in an in vitro and in vivo model of inflammatory bone loss.
• To investigate the underlying mechanism of Ag NP action on osteoclastogenesis and bone density.

Main Methods:

• Biosynthesis of Ag NPs using Flos Sophorae Immaturus extract.
• Establishment of an LPS-induced inflammatory bone loss model.
• Quantitative reverse transcription-polymerase chain reaction (RT-qPCR) and Western Blotting to assess gene and protein expression.
• Assessment of tartrate-resistant acid phosphatase-positive (TRAP+) cells and bone density in vivo.

Main Results:

• Synthesized Ag NPs demonstrated low toxicity and high stability.
• Ag NPs significantly reduced the number of TRAP+ cells and down-regulated key osteoclastogenic biomarkers.
• Ag NPs suppressed osteoclast formation by inhibiting ROS-mediated phosphorylation of the NF-κB pathway.
• In vivo studies showed Ag NPs ameliorated bone density and decreased osteoclast numbers.

Conclusions:

• Biosynthesized Ag NPs effectively inhibit osteoclast formation and activity.
• Ag NPs mitigate inflammatory bone loss by down-regulating ROS and NF-κB signaling.
• These findings highlight Ag NPs as a potential therapeutic agent for inflammatory bone loss.